Joshua T. Brumm

CIK: 0001528826

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CBIO

CRESCENT BIOPHARMA, INC.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

CBIO
CRESCENT BIOPHARMA, INC.
Sep 18, 2026
Sale(S)
Direct
7.8K shares at avg. $16.71$131K
CBIO
CRESCENT BIOPHARMA, INC.
Sep 16, 2026
Sale(S)
Direct
1.6K shares at avg. $17.90$29K
CBIO
CRESCENT BIOPHARMA, INC.
Jun 22, 2026
Sale(S)
Direct
42.3K shares at avg. $17.99$761K
CBIO
CRESCENT BIOPHARMA, INC.
Dec 15, 2025
Award(A)
Direct
45.1K shares-
CBIO
CRESCENT BIOPHARMA, INC.
Dec 15, 2025
Award(A)
Direct
10K shares-
CBIO
CRESCENT BIOPHARMA, INC.
Dec 8, 2025
Award(A)
Stock Option (Right to Buy)
Direct
345.7K shares-

		Type	Shares	Price		Ownership
Sep 18, 2026	CBIO CRESCENT BIOPHARMA, INC.	Sale(S)	7,837	$16.71	$130,956	Direct
Sep 16, 2026	CBIO CRESCENT BIOPHARMA, INC.	Sale(S)	1,610	$17.90	$28,819	Direct
Jun 22, 2026	CBIO CRESCENT BIOPHARMA, INC.	Sale(S)	42,305	$17.99	$761,067	Direct
Dec 15, 2025	CBIO CRESCENT BIOPHARMA, INC.	Award(A)	45,117	-	-	Direct
Dec 15, 2025	CBIO CRESCENT BIOPHARMA, INC.	Award(A)	10,000	-	-	Direct
Dec 8, 2025	CBIO CRESCENT BIOPHARMA, INC.	Award(A) Stock Option (Right to Buy)	345,672	-	-	Direct

1-6 of 6 transactions

About Brumm Joshua T

Brumm Joshua T (SEC CIK 0001528826) files insider reports with the SEC as Chief Executive Officer of CRESCENT BIOPHARMA, INC. (CBIO).

Signal8 holds 5 ownership filings by Brumm Joshua T (1 Form 3, 4 Form 4), filed between Jun 23, 2025 and Sep 18, 2026. Those filings report 6 transactions, from Dec 8, 2025 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Brumm Joshua T's filings is in WALTHAM, MA.

Recent filings by Brumm Joshua T

Sep 18, 2026: Open-market sale of CBIO shares (Form 4, code S).
Sep 16, 2026: Open-market sale of CBIO shares (Form 4, code S).
Jun 22, 2026: Open-market sale of CBIO shares (Form 4, code S).
Dec 15, 2025: Grants or awards of CBIO shares (2 lines, Form 4, code A).
Dec 8, 2025: Grant or award of CBIO derivative securities (Form 4, code A).

Other insiders filing for CRESCENT BIOPHARMA, INC. (CBIO)

Lynch Ryan
Pinkas Jan, Chief Scientific Officer
Im Ellie Eunkyung, Chief Medical Officer
Scalzo Richard William, Chief Financial Officer
Bispham Barbara Harlin
McNeill Jonathan, President and COO

How to read Form 4 transaction codes